Clinical trial NCT00472459: Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Official title: A Multicenter, Randomized Study of Photodynamic Therapy (PDT) With Metvix® 160 mg/g Cream in Immuno-compromised Patients With Non-melanoma Skin Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Actinic Keratosis
Warts
Basal Cell Carcinoma
Bowens Disease
Squamous Cell Carcinoma
Keywords: Non-melanoma skin cancer
Organ transplant recipients
Photodynamic therapy
Actinic keratosis
Lead sponsor: Galderma R&D
Sponsor class: INDUSTRY
First posted: 2007-05-11
Enrollment: 82
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Participants on immunosuppressive therapy, e.g., organ recipients, had higher occurrence of AK (Actinic Keratosis) than the untreated population. Keratotic lesions (i.e., AK lesions and warts) in this population were highly associated with development of SCC (Squamous Cell Carcinoma) also with 10 times higher mortality rate because of SCC than expected. The risk of developing skin cancer, predominantly SCC and BCC (Basal Cell Carcinoma), increased with graft survival time and the length of immunosuppressive treatment period.

The higher risk of developing skin malignancy and more aggressive skin malignancies in this population, indicated the need for early removal of these pre-malignant lesions.

In this study, two contralateral areas (5x10 cm\^2) with skin lesions within the participant were compared. One area was received Metvix PDT at defined intervals and the other was received lesion specific treatment at the discretion of the investigator. The primary endpoint was the accumulated number of new lesions during the study and number of AK lesions that showed complete response 3 months after baseline. Secondary endpoints were number of BCC lesions that showed complete response, number of recurrent lesions, assessment of cosmetic outcome and safety.

Detailed description: The treatment area (5x10 cm\^2) was treated at baseline and at 3 ,9 and 15 months visits. At baseline, the area was treated with fractionated Metvix® PDT treatment consisting of two treatment one week apart and at 3 ,9 and 15 months visits with single Metvix® PDT treatment. The participants were evaluated for occurrence of new lesions, lesion response and recurrence at 3 (not recurrence),9,15,21, and 27 months visits. New and recurrent lesions in the treated area were treated with Metvix® PDT treatment. Lesions with partial response in the treated area were re-treated with Metvix® PDT and lesions with no response were treated with lesion specific treatment at the discretion of the investigator.

In the contralateral control area (5x10 cm\^2), new and recurrent lesions and lesions in non-complete response were treated with lesion specific treatment at the discretion of the investigator at each study visit.

Eligibility criteria: Inclusion Criteria:

* Transplant recipients with at least 2 clinically diagnosed AK lesion and maximum 10 skin lesions (AK, BCC, SCC in situ and/or warts) in each of the two contralateral areas (diameter 5x10\^2 cm) in the face, the scalp, the extremities or on the trunk/neck.
* Transplant recipients who previously were treated more than once for their skin lesions.
* Transplant recipients who had received immunosuppressive therapy for more than 3 years.
* Males or females above 18 years of age.
* Written informed consent.

Exclusion Criteria:

* Participants with more than 10 skin lesions (AK, BCC, SCC in situ, warts) in one of the two areas.
* Participants with SCC (not SCC in situ) in one of the two areas.
* Participants not previously treated or treated only once for their skin lesions.
* Participants with rosacea in one of the two areas.
* Participants with morphea form/highly infiltrating BCC
* Known allergy to methyl-amino levulinate, a similar compound or excipients of the cream
* Participation in other clinical studies either concurrently or within the last 30 days.
* Pregnant or breast-feeding (all women of child-bearing potential documented a negative pregnancy test and used the pill or IUD during the treatments and for at least one month thereafter).
* Conditions associated with a risk of poor protocol compliance

Primary outcomes:
measure: Number of Accumulated New Skin Lesions at Month 3
timeFrame: At Month 3
measure: Number of Accumulated New Skin Lesions at Month 9
timeFrame: At Month 9
measure: Number of Accumulated New Skin Lesions at Month 15
timeFrame: At Month 15
measure: Number of Accumulated New Skin Lesions at Month 21
timeFrame: At Month 21
measure: Number of Accumulated New Skin Lesions at Month 27
timeFrame: At Month 27
measure: Number of AK Lesions That Showed Complete Response at Month 3
timeFrame: At Month 3
measure: Number of AK Lesions That Showed Complete Response at Month 9
timeFrame: At Month 9
measure: Number of AK Lesions That Showed Complete Response at Month 15
timeFrame: At Month 15
measure: Number of AK Lesions That Showed Complete Response at Month 21
timeFrame: At Month 21
measure: Number of AK Lesions That Showed Complete Response at Month 27
timeFrame: At Month 27
Secondary outcomes:
measure: Number of BCC Lesions That Showed Complete Response
timeFrame: At Months 3, 9, 15, 21 and 27
measure: Number of Recurrent Lesions
timeFrame: At Months 9, 15, 21 and 27
measure: Number of Participants With Overall Cosmetic Outcome Assessed by Investigator and Participants
timeFrame: At Month 27
measure: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
timeFrame: From Baseline up to Month 27
Other outcomes:
Locations:
city: Roskilde
country: Denmark
facility: Department of Dermatology, Roskilde Amysygehus
city: Århus
country: Denmark
facility: Department of Dermatology, Århus Amysygehus
city: Berlin
country: Germany
facility: Klinik für Dermatologie, Venerologie und Allergologie, Campus Charité Mitte
city: Hannover
country: Germany
facility: Hautklinik Linden
city: Oslo
country: Norway
facility: Department of Dermatology, Rikshospitalet
city: Trondheim
country: Norway
facility: Department of Dermatology, St. Olavs Hospital
city: Gothenburg
country: Sweden
facility: Department of Dermatology, Sahlgrenska University Hospital
city: Stockholm
country: Sweden
facility: Department of Dermatology, Karolinska University Hospital, Huddinge
city: Uppsala
country: Sweden
facility: Department of Dermatology, Uppsala University Hospital
city: Manchester
country: United Kingdom
facility: Dermatology Department, Manchester Royal Infirmary
city: Portsmouth
country: United Kingdom
facility: Portsmouth Dermatology Centre, St Mary's Hospital
Study officials:
affiliation: Sahlgrenska University Hospital
name: Ann-Marie Wennberg, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: